Fig. 2: All eleven proteasome inhibitors were tested for their ability to inhibit the activity at the β5 proteasome site. | Cell Death Discovery

Fig. 2: All eleven proteasome inhibitors were tested for their ability to inhibit the activity at the β5 proteasome site.

From: Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Fig. 2

Bortezomib and delanzomib show 95% and 55% inhibition at 1000 nM, and at 10000 nM they inhibit activity to 100% while MLN-9708 (51%), MLN-2238 (33%), and MG-132 (25%) inhibit the β5 site to a small extent. Statistically significant differences in the suppression of chymotrypsin-like activity in the proteasome between various doses of proteasome inhibitor were determined using the paired t-test. *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.

Back to article page